Kane Biotech Inc. Summarizes Compelling Oral Care Study Results
Mar 26 15
Kane Biotech Inc. provided a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations. The dog efficacy study was a controlled, randomized, masked study with 30 dogs each per control and treatment groups. Both groups were fed normal diets, but the treatment group received drinking water containing Kane's oral care water additive at the recommended dosage, while control group received normal water for consumption throughout the study period. On Day 0, dental prophylaxis was performed for each dog and calculus score was confirmed as a score of (0).Then calculus was measured on day 28, 56, 84 of the study period using modified Warrick-Gorrel method. The mean calculus scores for the company's oral care water additive were better than the control throughout the study. On day 28, 56, and 84 the calculus score for the water additive was 14.2%, 23.5%, and 25.4% lower than the control group, respectively. The difference in calculus scores between the control and treatment group was statistically significant. In addition, no significant differences were observed between the two treatment groups for either animal body weights or food consumption. 25.4% reduction in calculus (p<0.0229). No change in body weight or food consumption. The water additive is an effective first step in pet oral care. The dog safety study was a randomized, masked laboratory study with three parallel treatment groups each contained 6 dogs. The product was administered as added to their drinking water at 0, 1 and 5 times the recommended application volume. Dogs were treated for a total of 30 consecutive days. Variables measured included clinical observations, physical examinations, oral assessments, body weights, and clinical pathology that include a comprehensive list of hematology and serum chemistry indices, and coagulation profile measured at regular time points during study period. With the exception of soft feces (noted intermittently for 3 of 6 dogs in the 5 times use rate group) findings documented during clinical observations, physical examinations and oral assessments were within normal limits. Trends were similar across treatment and control groups. Evaluation of clinical pathology indices revealed no group trends or individual effects which were considered treatment-related. In conclusion, the safety study successfully demonstrated the product is safe up to 5 times the recommended usage rate during the study period. Passed comprehensive safety assessment up to 5 times usage rate. Contains ingredients that meet Health Canada's LRVHP (Low Risk Veterinary Health Program).
Kane Biotech Introduces bluestem™
Feb 12 15
Kane Biotech Inc. announced that it will be introducing the company’s bluestem pet oral care brand in the over the counter (OTC) retail market. bluestem™ is a specifically formulated oral care product that contains the company’s patent pending coactiv+™ technology. The initial product introduction will be a water additive for daily use in four flavours including original, vanilla mint, chicken and salmon, with additional product formulations to follow. bluestem is now available at select pet stores in Manitoba.
Kane Biotech Appoints Mark Nawacki to the Board of Directors
Oct 8 14
Kane Biotech Inc. announced the appointment of Mark Nawacki to its board of directors. Mark will be replacing Richard Cherney who is retiring from the board. Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin until September 2014. Mark joined Paladin in 2003 and was responsible for all business, corporate and product development activities.